Merck paused shipments of Gardasil to China in January. It said the decline was primarily in China, but lower demand in Japan ...

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include ...

If you're looking for high-yield stocks in the healthcare sector, it's hard to beat this trio of industry giants offering ...

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.2% in the afternoon session after the company reported second ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

Sales of Keytruda, which accounts for about half of Merck's revenue, grew by 9%, to $7.96 billion. Merck's main U.S. patent for the cancer treatment expires in 2028, opening the door for lower-cost ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...

Merck and Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.